Immutep tries again
After Tacti-003’s controlled cohorts fail, Immutep plays up single-arm data in PD-L1 non-expressers.
A second-line degrader battle beckons
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
Amgen packs up in Claudin6
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
Reality Bites again for Amgen
Micromet’s tech has yielded two marketed drugs, one still in the clinic... and 14 discontinuations.
